Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 10/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6993588 | 0.85 | CCR1 (0.48) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL7000018 | 0.85 | CCR1 (0.53) | CCR1FPR3GPR65GPR35S1PR5 | |
| SCHEMBL6999003 | 0.84 | CCR1 (0.41) | FAAHACHEBCHECCR1KDM4E | |
| SCHEMBL6998592 | 0.84 | MAPT (0.44) | FAAHACHEBCHEKDM4EMAPT | |
| SCHEMBL6997000 | 0.84 | CCR1 (0.49) | CCR1FPR3GPR65GPR35S1PR5 | |
| SCHEMBL7000591 | 0.83 | CCR1 (0.62) | CCR1FPR3GPR65GPR35S1PR5 | |
| SCHEMBL7004433 | 0.82 | CCR1 (0.49) | CCR1FPR3GPR65GPR35KMT2A | |
| SCHEMBL7001654 | 0.81 | CCR1 (0.38) | FAAHACHEBCHECCR1KDM4E | |
| SCHEMBL6997012 | 0.80 | KDM4E (0.52) | FAAHACHEBCHECCR1KDM4E | |
| SCHEMBL6993640 | 0.79 | CCR1 (0.59) | CCR1FPR3GPR65GPR35KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | FAAH 2760/4885ACHE 4839/4885BCHE 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.